McLean1.jpg (1194 bytes)MGHcjo.jpg (7744 bytes)HVDcjo.jpg (9168 bytes)

NRI
 Director: Prof. Ole Isacson, Biography and Research
Search
Contact

 


Home Up Seminars Parkinson's Huntington's

Alzheimer's

   

 

Novel Therapeutic Approaches for Parkinson's Disease
Parkinson's Disease Research Articles

There are compelling research opportunities for Parkinson’s disease (PD) therapeutics. While L-dopa provides an initial relief, there is a need for alternative strategies to deal with the continued loss of dopaminergic (DA) neurons, axons and terminals.

The NINDS Udall Parkinson's Disease Research Center of Excellence:

We have a functional collaborative scientific group centered at McLean Hospital and Harvard Primate Center funded by the NIH/NINDS that investigates neuroprotective, neuromodulatory and neural transplantation approaches for PD. We use animal models, including MPTP-treated animals with loss of dopamine cells, synapses and function. This Center is organized around 3 Cores that serve this and other NIH PD Centers, and 3 specific Projects that explore the shared theme of “Novel Therapeutic Approaches for Parkinson’s Disease”.

Project 1. Functional differences between dopamine (DA) neurons in the substantia nigra (A9) that are vulnerable to PD compared to those spared in the same midbrain tissue region A10 (VTA) are examined. We discovered new gene and molecular candidates for neuroprotection by specific laser-capture and genomic analysis of characteristic DA neurons, now tested systematically by tissue culture and animal models to identify new pathways and substances providing insights into the pathogeneses and novel therapies for PD. Project 1 links to NIH Udall Centers, including specific collaborations with Duke U Udall Center for genomic convergence analysis of PD susceptibility genes from bioinformatics, linkage analysis and finally functional tests in our PD model systems.

Project 2. Post-mitotic but immature DA neurons are derived from primate and human stem cells for restorative transplantation into sophisticated PD model primates (including functional tests and imaging - see Core B). Project 2 works with collaborators and NIH Udall Centers, and like Project 1 and 3 is internally served by Core A, B and C, and specifically by its transplantation in PD primate models linked to the supply of genetically engineered human stem cells produced in Project 3.

Project 3. Specific midbrain genes and transcription factors controlling DA neuron development are identified and engineered into mouse and human stem cells. The resulting DA neurons are tested for functional repair in PD models in collaborative experiments in the Center. By using combinations of factors, a large fraction of stem cell derived cultured TH-positive GFP labeled and midbrain mouse or human neurons are sorted for purity and safety by the Center’s advanced FACS technology before transplantation.

This PD Center also provides significant PD research education and training for scientists, and service to the PD patient and medical research communities. The Center’s 3 research projects and its integrated Administrative Core (Core A), Functional Imaging Core (Core B) and a Clinical Transplantation, Bioinformatics, Human and Stem Cell Marker Core (Core C) are unique components in the NIH Udall Center of Excellence Consortium. The Harvard-McLean NIH Parkinson's Disease Research Center of Excellence provides a specialized environment for synergistic PD research on stem cell derived therapies, novel insights into functional genetic analysis of vulnerability of midbrain DA neurons and cutting edge research of new modalities leading to novel treatments for PD patients.

 

 
Home Up Search Contact

MailmanRC.gif (6273 bytes)

 © All Rights Reserved.
Copyright © 2000 Center for Neuroregeneration Research
Site Contact: Sandra Pohlman -
nrladmin@mclean.harvard.edu

System Contact: PageServant
Last modified:
Tuesday, March 22, 2016